These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

627 related articles for article (PubMed ID: 29082652)

  • 1. Long-term outcome of telbivudine versus entecavir in treating higher viral load chronic hepatitis B patients without cirrhosis.
    Pan HY; Pan HY; Song WY; Zheng W; Tong YX; Yang DH; Dai YN; Chen MJ; Wang MS; Huang YC; Zhang JJ; Huang HJ
    J Viral Hepat; 2017 Nov; 24 Suppl 1():29-35. PubMed ID: 29082652
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of telbivudine plus adefovir dipivoxil combination therapy and entecavir monotherapy for HBeAg-positive chronic hepatitis B patients with resistance to adefovir dipivoxil.
    Lu JJ; Liu K; Ma YJ; Wang J; Chen EQ; Tang H
    J Viral Hepat; 2013 Apr; 20 Suppl 1():40-5. PubMed ID: 23458523
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of 208-week sequential therapy with telbivudine and entecavir in HBeAg-positive chronic hepatitis B patients with suboptimal responses to 24 weeks of Peg-IFNα-2a therapy: An open-labelled, randomized, controlled, "real-life" trial.
    Luo XD; Chen XF; Zhou Y; Chen XP
    J Viral Hepat; 2017 Nov; 24 Suppl 1():36-42. PubMed ID: 29082651
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of efficacy and renal safety of telbivudine and entecavir in treatment-naive elderly patients with chronic hepatitis B.
    Law ST; Lee MK; Li KK; Mok CK
    Eur J Gastroenterol Hepatol; 2016 Feb; 28(2):193-8. PubMed ID: 26587867
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of telbivudine and entecavir for HBeAg-positive chronic hepatitis B: a meta-analysis.
    Su QM; Ye XG
    World J Gastroenterol; 2012 Nov; 18(43):6290-301. PubMed ID: 23180951
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effectiveness of entecavir or telbivudine therapy in patients with chronic hepatitis B virus infection pre-treated with interferon compared with de novo therapy with entecavir and telbivudine.
    Cai S; Cao J; Yu T; Xia M; Peng J
    Medicine (Baltimore); 2017 Jun; 96(22):e7021. PubMed ID: 28562554
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Telbivudine versus lamivudine and entecavir for treatment-naïve decompensated hepatitis B virus-related cirrhosis.
    Yue-Meng W; Li YH; Wu HM; Yang J; Xu Y; Yang LH; Yang JH
    Clin Exp Med; 2017 May; 17(2):233-241. PubMed ID: 27094312
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Entecavir to Telbivudine Switch Therapy in Entecavir-Treated Patients with Undetectable Hepatitis B Viral DNA.
    Kim DH; Choi JW; Seo JH; Cho YS; Won SY; Park BK; Jeon HH; Shin SY; Lee CK
    Yonsei Med J; 2017 May; 58(3):552-556. PubMed ID: 28332360
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparing Efficacy of Lamivudine, Adefovir Dipivoxil, Telbivudine, and Entecavir in Treating Nucleoside Analogues Naïve for HBeAg-Negative Hepatitis B with Medium Hepatitis B Virus (HBV) DNA Levels.
    Shi H; Han Z; Liu J; Xue J; Zhang S; Zhu Z; Xia J; Huang M
    Med Sci Monit; 2017 Nov; 23():5230-5236. PubMed ID: 29095799
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hepatitis B surface antigen quantification at hepatitis B e antigen seroconversion predicts virological relapse after the cessation of entecavir treatment in hepatitis B e antigen-positive patients.
    Qiu YW; Huang LH; Yang WL; Wang Z; Zhang B; Li YG; Su TT; Zhou HY; Xu W; Wang XD; Dai YP; Gan JH
    Int J Infect Dis; 2016 Feb; 43():43-48. PubMed ID: 26523639
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Potential Effects of Telbivudine Versus Entecavir on Renal Function in Patients With Chronic Hepatitis B Virus Receiving Glucocorticoids Therapy.
    Liu B; Shen B; Mei M; Li L; Wang X; Zhao H
    Ther Apher Dial; 2020 Feb; 24(1):56-63. PubMed ID: 31090170
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of clinical efficacy and renal safety of telbivudine and entecavir in chronic hepatitis B patients receiving cytotoxic chemotherapy.
    Law ST; Lee MK; Lee AS; Tung Y; Li KK
    J Dig Dis; 2016 May; 17(5):325-33. PubMed ID: 27085094
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A comparison of telbivudine and entecavir in the treatment of hepatitis B e antigen-positive patients: a prospective cohort study in China.
    Zhang Y; Hu P; Qi X; Ren H; Mao RC; Zhang JM
    Clin Microbiol Infect; 2016 Mar; 22(3):287.e1-9. PubMed ID: 26548508
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Clinical effect of entecavir versus tenofovir in treatment of HBeAg-positive chronic hepatitis B patients with a high viral load: a comparative analysis].
    Shi H; Li XY; Zhu JY; Lin CS; Zhang Y
    Zhonghua Gan Zang Bing Za Zhi; 2017 Oct; 25(10):721-725. PubMed ID: 29108198
    [No Abstract]   [Full Text] [Related]  

  • 15. [Short-term results of telbivudine versus entecavir treatments in HBeAg-positive chronic hepatitis B patients in China].
    Shi KQ; Zhang DZ; Guo SH; He H; Wang ZY; Shi XF; Zeng WQ; Ren H
    Zhonghua Gan Zang Bing Za Zhi; 2008 Sep; 16(9):641-5. PubMed ID: 18822200
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ten-year follow-up of hepatitis B relapse after cessation of lamivudine or telbivudine treatment in chronic hepatitis B patients.
    Pan HY; Pan HY; Chen L; Yang DH; Huang HJ; Tong YX; Chen CR; Yan J
    Clin Microbiol Infect; 2015 Dec; 21(12):1123.e1-9. PubMed ID: 26253290
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparing the efficacy and clinical outcome of telbivudine and entecavir naïve patients with hepatitis B virus-related compensated cirrhosis.
    Tsai MC; Yu HC; Hung CH; Lee CM; Chiu KW; Lin MT; Tseng PL; Chang KC; Yen YH; Chen CH; Hu TH
    J Gastroenterol Hepatol; 2014 Mar; 29(3):568-75. PubMed ID: 24716215
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of telbivudine compared with entecavir in hepatitis B virus-related cirrhosis: 2 year follow-up data.
    Kim HR; Yim HJ; Kang S; Suh SJ; Kim SY; Hyun JJ; Koo JS; Kim JH; Seo YS; Yeon JE; Lee SW; Byun KS; Um SH
    Liver Int; 2015 Mar; 35(3):860-9. PubMed ID: 24905912
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Switching from entecavir to PegIFN alfa-2a in patients with HBeAg-positive chronic hepatitis B: a randomised open-label trial (OSST trial).
    Ning Q; Han M; Sun Y; Jiang J; Tan D; Hou J; Tang H; Sheng J; Zhao M
    J Hepatol; 2014 Oct; 61(4):777-84. PubMed ID: 24915612
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Efficacy of 104-week sequential therapy with telbivudine or entecavir in HBeAg-positive chronic hepatitis B patients with suboptimal responses to 24-week therapy with pegylated interferon-α-2a].
    Luo XD; Chen XP; Chen R; Chen XF; Huang J
    Zhonghua Gan Zang Bing Za Zhi; 2016 Apr; 24(4):241-5. PubMed ID: 27470620
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 32.